Camilla is CEO and Board Member at Zehna Therapeutics.

Camilla has over 25 years of US and International business and strategy experience across a diverse group of organizations: from seed investments to public multinational companies. Camilla has a proven track record in delivering novel products for multiple disease indications to global markets in areas of high unmet medical need. Her key accomplishments include the registration of Brineura® for CLN2 Batten’s Disease, Xagrid® for Essential Thrombocythemia, Fosrenol® for Hyperphosphatemia in CKD and Solaraze® for Actinic Keratosis. Prior to Zehna, Camilla founded Rare Strategic LLC where she provided strategic advice to early stage venture-backed companies. Camilla has held numerous executive leadership positions, including SVP, Head of Product Portfolio Development at BioMarin Pharmaceutical Inc., Global Head of Regulatory Affairs at BioMarin Pharmaceutical Inc., and VP Global Regulatory Strategy- Early Development and Business Development at Shire Pharmaceuticals. At Shire she was part of acquisition team for Movetis, Sarcode BioSciences, Ferrokin BioSciences and Advanced BioHealing. Camilla serves on the boards of Dyve Biosciences and Spruce Biosciences.

Camilla received a BSc from National University of Ireland, Galway, a BSc Hons, from Kingston University, UK, and an MSc with distinction from Birkbeck College, University of London.